Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM
Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet...
News
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in...
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its...
Alignment Healthcare to Announce Third Quarter 2024 Financial Results and Host Conference Call Tuesday, Oct. 29, 2024
ORANGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its third quarter 2024 financial...
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) , a neurotech company...
UPDATE — Better Choice Company Chairman Issues Letter to Shareholders as Company Continues to Make Progress Towards the Closing of its SRx Health Acquisition
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets,...
Phase III trial results of novel triple combination pill for hypertension published in The Lancet
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced...
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK, 18 October 2024 – ViaNautis Bio (“ViaNautis” or...
KFSHRC Leads Healthcare Intelligence in Diagnostics and Patient Care
RIYADH, Saudi Arabia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is contributing to...
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence,...
Better Choice Company Chairman Issues Letter to Shareholders as Company Continues to Make Progress Towards the Closing of its SRx Health Acquisition
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets,...
Nxera Pharma to Host R&D Day 2024
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be...
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an...
Telix Files Form 20-F Registration Statement for Nasdaq ADS
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has...
Laguna Treatment Center Sets Standard for Veteran Addiction Care in Southern California with New PsychArmor Certification
ALISO VIEJO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Laguna Treatment Center is among an elite group of addiction treatment...
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data...
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
LifeStance to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024
SCOTTSDALE, Ariz., Oct. 17, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers...